Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel in platinum-refractory ovarian cancer (phase II)
2012-001224-35Phase 2Terminated
- Sponsor
- Vejle Hospital
- Start
- Jul 2012
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel in Ovarian Epithelial Adenocarcinoma, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Vejle Hospital. Primary endpoint: Objective response rate. Started Jul 2012; status: terminated.
02
Drugs
cabazitaxel
03
Conditions
Ovarian Epithelial Adenocarcinomafallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2012-001224-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001224-35.